It is very possible that the Mylan Pharmaceuticals saga will end not with a bang, but with a whimper. Now that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has decided to seek its fortunes elsewhere by acquiring the generic division of Allergan, Migdal Capital Markets believes that the Mylan's acquisition of Perrigo Company (NYSE:PRGO; TASE:PRGO) at a $32 billion value for Perrigo may not go through. RELATED ARTICLES Win-win situation for Teva and Mylan Analysts prefer Allergan deal over Mylan for Teva Mylan invokes "poison pill" to block Teva takeover According to Migdal Capital Markets pharmaceutical analyst Steven Tepper, "Perrigo saw how Mylan behaved with Teva, and I am not sure that Perrigo would want to get into bed with it. Mylan has less leverage now; it wanted to acquire Perrigo on the basis of a share value inflated by the Teva offer, and now it cannot do this. "With a share at $50, say, Mylan will have to significantly dilute its shareholders in order to acquire Perrigo, and it will certainly be difficult for Perrigo's shareholders with a deal that makes sense." Published by Globes [online], Israel business news - www.globes-online.com - on July 27, 2015© Copyright of Globes Publisher Itonut (1983) Ltd. 2015
